Payment overview · 2025
General Payments
$52.81
3 reported records · 2 companies
Healthcare provider profile · identity verified
Stephen John Mitrosky, DO
Allopathic & Osteopathic Physicians|Internal Medicine · FRANKLIN, PA · NPI 1245279546
Verified facts
What the public records show
CMS Open Payments records show Stephen John Mitrosky, DO received $52.81 in general payments during 2025 across 3 reported records.
Insulet Corporation accounted for 74.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $39.09 | 74.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.72 | 26.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $52.81 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 235 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
235 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 684 | 140 |
| Ozempic | Semaglutide | 662 | 101 |
| Metformin Hcl Er | Metformin Hcl | 563 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 452 | 118 |
| Jardiance | Empagliflozin | 407 | 76 |
| Lisinopril | Lisinopril | 362 | 92 |
| Losartan Potassium | Losartan Potassium | 288 | 74 |
| Pioglitazone Hcl | Pioglitazone Hcl | 278 | 67 |
| Gabapentin | Gabapentin | 243 | 56 |
| Eliquis | Apixaban | 235 | 41 |
| Omeprazole | Omeprazole | 232 | 54 |
| Simvastatin | Simvastatin | 231 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 214 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 201 | 57 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 185 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 182 | 54 |
| Tresiba Flextouch U-200 | Insulin Degludec | 172 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 41 |
| Atenolol | Atenolol | 149 | 34 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 136 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 29 |
| Allopurinol | Allopurinol | 133 | 34 |
| Metformin Hcl | Metformin Hcl | 130 | 31 |
| Potassium Chloride | Potassium Chloride | 125 | 29 |
| Furosemide | Furosemide | 117 | 34 |
| Valsartan | Valsartan | 112 | 25 |
| Trazodone Hcl | Trazodone Hcl | 111 | 26 |
| Tramadol Hcl | Tramadol Hcl | 109 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 28 |
| Humalog Kwikpen U-100 | Insulin Lispro | 106 | 34 |
| Alendronate Sodium | Alendronate Sodium | 97 | 29 |
| Trulicity | Dulaglutide | 87 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 85 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 28 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 21 |
| Novolog Flexpen | Insulin Aspart | 70 | 22 |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 67 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 19 |
| Alprazolam | Alprazolam | 65 | 11 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Spironolactone | Spironolactone | 63 | 16 |
| Pregabalin | Pregabalin | 62 | suppressed |
| Synthroid | Levothyroxine Sodium | 61 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 13 |
| Montelukast Sodium | Montelukast Sodium | 57 | 15 |
| Farxiga | Dapagliflozin Propanediol | 56 | 14 |
| Meloxicam | Meloxicam | 54 | 13 |
| Victoza 3-Pak | Liraglutide | 54 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 16 |
| Famotidine | Famotidine | 53 | 12 |
| Sertraline Hcl | Sertraline Hcl | 49 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Carvedilol | Carvedilol | 47 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 14 |
| Bumetanide | Bumetanide | 44 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 43 | 13 |
| Humalog | Insulin Lispro | 42 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 11 |
| Baclofen | Baclofen | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | 16 |
| Droplet Pen Needle | Pen Needle, Diabetic | 37 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | suppressed |
| Irbesartan | Irbesartan | 34 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 34 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Admelog Solostar | Insulin Lispro | 32 | 11 |
| Rybelsus | Semaglutide | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Nystatin | Nystatin | 31 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 30 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 12 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 15 |
| Diazepam | Diazepam | 27 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Repaglinide | Repaglinide | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Nyamyc | Nystatin | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 11 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 11 |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Fragmin | Dalteparin Sodium,porcine | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $52.81 · 3 records | Insulet Corporation | ELIQUIS, NURTEC ODT, Omnipod | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error